Iovance Biotherapeutics, Inc. is a commercial-stage biotechnology company that develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers. The company also offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma, and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.

Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer.

We are adding to our talented team as we actively prepare for our initial commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida. 

Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings 


Broadfin Capital

OrbiMed

Quogue Capital

Frazier Healthcare Partners

Iovance Biotherapeutics, Inc.

We're proud to share that the @US_FDA
 has granted accelerated approval for our therapy for advanced melanoma.
Learn more: https://lnkd.in/etxeMZUK

Today Iovance reported fourth quarter and full year 2023 financial results and corporate updates. We will host an audio webcast at 4:30 pm ET, please join us for the live webcast or listen to the replay: https://lnkd.in/dDyHAfWs 

We recently became aware of a phishing scam targeting potential applicants with fraudulent job offers. Please be advised that Iovance will never ask you to download a messaging app, provide personal information via text message, or require any financial commitment during the recruitment process. For more information on how to spot a job scam, please visit: https://lnkd.in/ee-QjXfX.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

COM:IOVANCE

Iovance Biotherapeutics, Inc.

Last Close

11.38

30/08 20:00

Market Cap

2.18B

Beta: -

Volume Today

3.96M

Avg: -

Analysis Not Available